- Comparison of Patients Treated with Natalizumab and Interferon-Beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211) will be available for viewing on Monday, March 18, 2013 from 2:00 to 6:30 p.m. PDT
House Democrats start probe into MS drug prices
'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'
All eyes are on Pfizer in the months ahead.
Pfizer post earnings beat.
The Justice Department is investigating the company's charitable contributions for kickbacks and false claims.